Chronic News and Research

RSS

Botox injections may improve frequency of chronic daily and migraine headaches

Although botulinum toxin A injections are U.S. Food and Drug Administration approved for preventive treatment for chronic migraines, a review and analysis of previous studies finds a small to modest benefit for patients with chronic migraine headaches and chronic daily headaches, although botox injections were not associated with greater benefit than placebo for preventing episodic migraine or chronic tension-type headaches, according to an article in the April 25 issue of JAMA.

24 Apr 2012

HDAC6 protein may provide novel target for stress-linked disorders

A cellular protein called HDAC6, newly characterized as a gatekeeper of steroid biology in the brain, may provide a novel target for treating and preventing stress-linked disorders, such as depression and post-traumatic stress disorder (PTSD), according to research from the Perelman School of Medicine at the University of Pennsylvania.

24 Apr 2012

Bartonella bacterium may also play a role in human arthritis

A bacterium historically associated with cat scratch fever and transmitted predominately by fleas may also play a role in human rheumatoid illnesses such as arthritis, according to new research from North Carolina State University.

24 Apr 2012

Nephros granted rights to market products based on Medica's Medisulfone ultrafiltration technology

Nephros, Inc., a medical device company developing and marketing filtration products for therapeutic applications, infection control, and advanced water purification solutions, today announced that the company has entered into a strategic license and supply agreement with Medica S.p.A.

23 Apr 2012

Enrollment complete for In-tunnel SeptRx European PFO Trial in Europe

SeptRx, an emerging medical device company that has developed the SeptRx Intrapocket PFO Occluder (IPO), reported today that it has completed enrollment for its "InterSEPT" (In-tunnel SeptRx European PFO Trial) clinical trial in Europe, and has entered into a partnership with CoRRect Medical GmbH for commercial distribution in Germany and Switzerland of the SeptRx IPO.

23 Apr 2012

FDA extends review period for linaclotide NDA to treat constipation

Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) notified the companies that it will require a three-month extension to complete its review of the data supporting the New Drug Application (NDA) for linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC).

23 Apr 2012

South African sports medicine expert to present at AMSSM annual meeting

South African sports medicine expert Martin Schwellnus, MD, PhD will be presenting "Born to Break Down? Genetics in Soft Tissue Injuries" at the 21st American Medical Society for Sports Medicine Annual Meeting in Atlanta, GA on April 22, 2012.

23 Apr 2012

Moxonidine drug can improve heart function and reduce blood pressure

Heart failure is the most common cause of death throughout the world, typically the result of chronic high blood pressure, also known as hypertension. As a result, research efforts have focused on an array of approaches aimed at preventing and treating high blood pressure. Recently, Japanese researchers examined the utility of an anti-hypertensive drug, moxonidine, which acts on the imidazoline receptors in the cardiovascular center of the brainstem.

23 Apr 2012

Avocado oil protects against free radicals in mitochondria

Atmospheric oxygen facilitated the evolution and complexity of terrestrial organisms, including human beings, because it allowed nutrients to be used more efficiently by those organisms, which in turn were able to generate more energy. However, as we find out more about how oxygen molecules work inside the body, more attention is being paid to their not-so-good effects, and researchers are seeking ways to thwart them.

23 Apr 2012

Autophagy potential target for new CF treatments

Scientists have found why a certain type of bacteria, harmless in healthy people, is so deadly to patients with cystic fibrosis.

23 Apr 2012

HBO2 therapy can reduce neuropathic pain

Chronic pain affects about 76 million people in the U.S. and carries an economic burden of nearly $100 billion annually. The most frequently used medications, narcotic and non-narcotic analgesic drugs (e.g., morphine, ibuprofen, etc.), do not provide complete or sustained relief of chronic pain. Scientists are currently seeking alternative solutions for chronic pain management.

23 Apr 2012

Scripps Florida scientist to develop new tests for aging and stress-associated diseases

A scientist from the Florida campus of The Scripps Research Institute has been awarded just over $1 million from the National Institutes of Health to develop a range of new tests that could lead to new treatments for a number of stress-associated and degenerative disorders of advancing age.

21 Apr 2012

Malawi's Mutharika left 'positive legacy' by showing how Africa 'can feed itself'

Malawi's President Bingu wa Mutharika, who died April 5, may be remembered for corruption and mismanagement, but his "positive legacy" is his creation of "an agriculture-led boom in Malawi, one that pointed a way for Africa to overcome its chronic hunger, food insecurity, and periodic extreme famines," Jeffrey Sachs, director of the Earth Institute at Columbia University, writes in a New York Times opinion piece.

21 Apr 2012

EMA CHMP recommends approval of AMAG’s ferumoxytol

AMAG Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the approval of ferumoxytol, an intravenous (IV) iron therapy, for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease.

21 Apr 2012

Updated results from CircuLite’s Synergy miniature ventricular support system clinical study

CircuLite, Inc. today announced that updated clinical data related to the Synergy miniature ventricular support system was presented in two oral presentations and one poster session at the International Society for Heart and Lung Transplantation's 32nd Annual Meeting and Scientific Sessions (ISHLT) in Prague, Czech Republic.

21 Apr 2012

First study to examine soda's effect on stroke risk

Researchers from Cleveland Clinic's Wellness Institute and Harvard University have found that greater consumption of sugar-sweetened and low-calorie sodas is associated with a higher risk of stroke. Conversely, consumption of caffeinated or decaffeinated coffee was associated with a lower risk.

21 Apr 2012

New data from descriptive sub-analysis of patients with compensated liver cirrhosis

New data from a descriptive sub-analysis of patients with compensated liver cirrhosis show that up to 43 percent of genotype-1a (GT1a) and up to 71 percent of GT1b hepatitis C virus (HCV) patients achieved sustained viral response (SVR12). SVR12 has been highly correlated with SVR24, which is a recognized indicator of viral cure.

20 Apr 2012

Researchers revisit Charcot's vibration therapy for Parkinson's disease

In the 19th century, Jean-Martin Charcot, the celebrated neurologist, developed a "vibration chair," to relieve symptoms of Parkinson's disease. Charcot reported improvements in his patients, but he died shortly thereafter and a more complete evaluation of the therapy was never conducted.

20 Apr 2012

Nanoscale films promote bone growth

Every year, more than a million Americans receive an artificial hip or knee prosthesis. Such implants are designed to last many years, but in about 17 percent of patients who receive a total joint replacement, the implant eventually loosens and has to be replaced early, which can cause dangerous complications for elderly patients.

20 Apr 2012

New data provides hope for HCV non-responders

New data from a number of clinical trials presented for the first time at the International Liver Congress- 2012 provides hope for previously difficult to treat hepatitis C (HCV) patient populations.

20 Apr 2012